Madrigal Pharmaceuticals Inc (MDGL)
210.82
+6.80
(+3.33%)
USD |
NASDAQ |
May 01, 16:00
210.82
0.00 (0.00%)
After-Hours: 17:02
Madrigal Pharmaceuticals Cash from Financing (TTM): 595.12M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 595.12M |
| September 30, 2023 | 379.54M |
| June 30, 2023 | 359.96M |
| March 31, 2023 | 366.14M |
| December 31, 2022 | 313.45M |
| September 30, 2022 | 68.62M |
| June 30, 2022 | 89.72M |
| March 31, 2022 | 104.14M |
| December 31, 2021 | 171.24M |
| September 30, 2021 | 156.36M |
| June 30, 2021 | 135.61M |
| March 31, 2021 | 72.18M |
| December 31, 2020 | 5.088M |
| September 30, 2020 | 0.459M |
| June 30, 2020 | 0.144M |
| March 31, 2020 | 0.152M |
| December 31, 2019 | 0.235M |
| September 30, 2019 | 0.845M |
| June 30, 2019 | 1.261M |
| March 31, 2019 | 314.15M |
| December 31, 2018 | 314.34M |
| September 30, 2018 | 449.25M |
| June 30, 2018 | 448.80M |
| March 31, 2018 | 170.67M |
| December 31, 2017 | 173.80M |
| Date | Value |
|---|---|
| September 30, 2017 | 44.23M |
| June 30, 2017 | 45.86M |
| March 31, 2017 | 17.10M |
| December 31, 2016 | 14.45M |
| September 30, 2016 | 9.85M |
| June 30, 2016 | -27.01M |
| March 31, 2016 | 6.361M |
| December 31, 2015 | 3.30M |
| September 30, 2015 | -0.359M |
| June 30, 2015 | 60.69M |
| March 31, 2015 | 75.37M |
| December 31, 2014 | 85.30M |
| September 30, 2014 | 144.46M |
| June 30, 2014 | 118.43M |
| March 31, 2014 | 64.38M |
| December 31, 2013 | 69.04M |
| September 30, 2013 | 70.26M |
| June 30, 2013 | 94.42M |
| March 31, 2013 | 94.74M |
| December 31, 2012 | 115.52M |
| September 30, 2012 | 57.37M |
| June 30, 2012 | 33.29M |
| March 31, 2012 | 67.68M |
| December 31, 2011 | 36.74M |
| September 30, 2011 | 41.90M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.144M
Minimum
Jun 2020
595.12M
Maximum
Dec 2023
148.43M
Average
89.72M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
| Eli Lilly and Co | 3.496B |
| Viking Therapeutics Inc | 873.23M |
| Akero Therapeutics Inc | 353.32M |
| 89bio Inc | 513.11M |
| Geron Corp | 362.02M |